PRI Health Care Alert

View this email in your browser ([link removed])
[link removed]
Vance's Critics Wrong: No Need to Fear High-Risk Pools
Newsmax | October 15, 2024 | Sally Pipes

Following the recent vice-presidential debate, Sen. J.D. Vance, R-Ohio, continues to face attacks on his ideas for covering people with pre-existing conditions.

Vance’s critics call his proposal — which would separate out sicker patients into a separate high-risk insurance pool — inhumane and impractical.

As Arthur Caplan, the head of medical ethics at NYU Grossman School of Medicine told NBC News, “Anything that separates out pre-existing conditions is doomed to utter failure.”

There’s plenty of evidence to suggest otherwise.
Read here . . . ([link removed])
Price Controls are Harming Doctors
Townhall | Wayne Winegarden | October 14, 2024

Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach.

As I document in a recent analysis, the government has imposed backdoor price controls on physicians by allowing inflation to significantly erode Medicare’s provider reimbursement rates. Over the decade between 2013 and 2022, while the cost of living increased by 27.4%, Medicare has increased its provider reimbursement rates by 1.3%.
Read more... ([link removed])

------------------------------------------------------------

New Schizophrenia Drug Represents Promise of Pharmaceutical Innovation
Forbes | Sally Pipes | October 15, 2024

Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side effects that have characterized previous schizophrenia treatments.

The drug’s journey from the lab through regulatory approval is a case study in how America’s world-class scientists work to bring groundbreaking cures to patients. At a time when many progressive lawmakers are actively working to disrupt this system—and see the pharmaceutical industry as a piggy bank for funding all manner of government spending—Cobenfy serves as a reminder for what works, and why our market-oriented system is worth preserving.
Read more.. ([link removed]) . ([link removed])
[link removed]

============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** YouTube ([link removed])
** LinkedIn ([link removed])
** Instagram ([link removed])
** Website ([link removed])
Copyright © 2024 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
P.O. Box 60485 Pasadena, CA 91116

** ([link removed])

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.